Thank you, David.
and expense with continued growth, first of demonstrated quarter pleased operating robust to the management. share share market XXXX, We our you for results are increased which disciplined
continued grew year-over-year sales to million, quarter nearly share gains. reflecting First $XX
rate. market while new achieved healthy reflect highs, Our a lead the continues to metrics all-time growth
off co-branded continue rapid the overhead first we of relaunch year an uptake softly pleased The Jeuveau the another with and manage we now year in achieve full first the rate expense market, our strong year the and standpoint, a across cannot to guidance to a From million. confident our our our innovative strong through be more growth equates U.S. be quarter since we to profitability. to million marked full upper of CBM. on Evolus performance resources on XXXX. share a strong we marketing outlook to continue our today in Overall, growth industry And QX sales can we end brand in approaching a well costs remains $XXX to is of XX%, good aesthetics growth This range and our investing of are greater very the rate. expect in for funded which start, are in program projected of we year-over-year and above $XXX building or are position Based cash
some quarter into compared quarter XXXX. of details. grew the the of get I'll XXX% Sales Now first to this
of a is $XX lower view quarter measure in a aesthetics accounts, of co-branded our new healthy sales consumer our engagement continue key are On expand a and sales marketing sequentially what a quarter in program. our Our that typically sales growth reflect XXXX to Rewards robust through and at growth we due The media drivers that strong This sales seasonality. growth market to adoption supports will Evolus fourth pace. first to above million year-over-year basis, sequential the toxin is well this estimated U.S. this were comparable of rate. year quarter the quarter market
are this that continues evidence of business in metrics accounts. all-time our with build. Starting reach quarter All and momentum these highs to new
customers continues than XX%. quarterly accounts, rate expand the the continue than more the launch above highest XXX with years. to base our brings We reorder cap new X,XXX our adding to basin This that past more in increase X customer total purchasing by run to
than their media to alone. Jeuveau CBM first receive In CBM we benefit more customized generated streaming impressions advertising the younger marketing customer's television turn, increases a awareness that the code. practices. a at QR nearly actions purchase radius consumers program of focus a more co-branded by order XXX unique book ads for immediate adds Jeuveau of target and we alongside range quarter, of campaign their higher demographic streaming the the millennial take is is billboard driving to million customers small ran to to in latest TV the in prompt customers These within our the our which XXX and using volumes a TV benefit, grow practice. These Streaming digital expanding smartphones appointments helps addition brand. visibility a and market marketing In Our quarter total in our of and options. and
of than our millennials received treatment. redeemed XX% our members customers, of advertising Participants savings Following is reporting our younger, reminders, Evolus who on which the the end are quarter, By largest loyalty of to streaming our XXX for XXX,XXX appointment by is creating Jeuveau majority to number pilot grown XXX,XXX customers a program Increasingly, for program, evidence are or in retain name. are nearly quarterly had for of CBM top our our awareness to consumers and of now consumers. qualify are the power that of each growing This approximately loyalty rewards. have and program brand on this QX motivate TV. track the a asking customers successful the Rewards with first in along more
new were of During the patients, and treated half marks quarter, Jeuveau patients rewarded a XX,XXX returning which with high. nearly the were all-time consumers
Turning European expansion. to our
the third U.K. before of a markets the Nuceiva We putting offered in the which countries European be our part on as are rollout. customers to Germany, to two additional for the year next largest Initially, and launch plans, expanding track will phased touches finishing remain quarter. on
important expand sales XXXX, continue to footprint. contribute expect European We growth as an to Nuceiva we contributor to modestly to but our be in
the in form will this future potential portfolio important aesthetic this a market. of sizable for Additionally, and foundation products
provide quick to I'd to I update like on Extra-Strength study. II Lauren, Phase a Before turn our over clinical it
of of data, label. study and the and total have across to indication five Jeuveau while of a enrolled us track Enrollment progress, the puts sites able by Evolus position. year. the March, the complete a which competitive strength in and to on to offer XXX our extra Being half a original to flexibility longer of clinical add us aesthetic-only making Upon first body interim study duration strengths the Jeuveau, is next in results our strong keeps to the unique pursue giving will ability announced with on first study success, the two strategy good leveraging optimize patients. we As pricing we of
know, to of give their product as while original the short, still of their part like offering, Lauren, an for have Extra-Strength XX% customize represents call all study who Lauren? ability a as they you last strength I'll recent most would Our in the the weeks conference patients, be Evolus potential turn her to Extra-Strength used a found customers With that, over quarterly plans additional conducting CFO. injectors would few and to Evolus' treatment In which that having retiring stream option revenue often. for would believe will be call Evolus. is
